A study to evaluate efficacy of single dose Benralizumab (Fasenra) treatment for difficult-to-treat adult asthma

A study to evaluate efficacy of single dose Benralizumab (Fasenra) treatment for difficult-to-treat adult asthma - A study to evaluate efficacy of single dose Benralizumab (Fasenra) treatment for difficult-to-treat adult asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032383

Enrollment

Registered

2018-04-30

Start date

2018-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aspirin exacerbated respiratory disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients diagnosed with aspirin exacerbated pulmonary disease (AERD) by a systemic aspirin provocation test or a history of characteristic respiratory reactions upon ingestion of COX-1 inhibitors. 2)A blood eosinophil level of 150 cells or more per microliter. 3)Able to provide written, signed and dated informed consent

Exclusion criteria

Exclusion criteria: 1) Previous treatment with benralizumab and mepolizumab in the past year. 2) Unable to provide written, signed and dated informed consent 3) Patients considered at risk of sinusitis and/or nasal polyp surgery during the study period 4) Patients with comorbidities (renal, hepatic, heart, mental, and malignancy etc) requiring treatment 5) Pregnancy, breast-feeding, or potential pregnancy 6) Patients considered unsuitable by the attending physician

Design outcomes

Primary

Measure	Time frame
change from baseline to week 4 in Sino-Nasal Outcome Test (SNOT22) score	—

Countries

Japan

Contacts

Public ContactYosuke Kamide

Sagamihara National Hospital Clinical Research Center for Allergy and Rheumatology

m08702012@gunma-u.ac.jp042-742-8311

Outcome results